Table 1 Cutaneous manifestations following COVID-19 vaccines in Iran

1

Extensive rash and edema

77

Female

Hypertension

Negative

ChAdOx1-S

2 days after the 1st dose

[20]

2

Radiation Recall Dermatitis

50

Female

History of breast cancer and radical mastectomy

Not stated

BBIBP-CorV

1 week after the 2nd dose

[21]

3

Erythemato-violaceous and sclerotic lesions

70

Female

-

Negative

ChAdOx1-S

2 days after the 1st dose

[22]

4

Panniculitis

40

Female

-

Not stated

Sputnik V

13 days after the 1st dose

[23]

5

Alopecia areata

23

Female

-

Not stated

ChAdOx1-S

1 week after the 1st dose

[24]

6

74

Male

Fatty liver

Not stated

BBIBP–CorV

2 days after the 2nd dose

[25]

7

37

Male

-

Not stated

BBIBP–CorV

6 days after the both doses

[25]

8

Herpes simplex

63

Female

Rheumatoid arthritis

Not stated

BBIBP–CorV

7 days after the 2nd dose

[26]

9

Toxic Epidermal Necrolysis (TEN)

76

Male

Atorvastatin 10 mg/day taken for several years

Not stated

BBIBP–CorV

1 day after vaccination

[27]

10

71

Male

–

Not stated

BBIBP–CorV

10 days after the 1st dose

[25]

11

Pemphigus vulgaris (PV)

76

Female

Diabetes mellitus, hyperlipidemia, and ischemic heart disease

Not stated

BBIBP–CorV

1 month after the 2nd dose

[28]

12

30

Female

–

Not stated

BBIBP–CorV

16 days after 1st dose

[25]

13

New-onset lichen planus (LP)

52

Female

–

Positive

BBIBP–CorV

1 week after the 2nd dose

[29]

14

45

Female

Hypertension

Not stated

BBIBP–CorV

14 days after the 1st dose

[25]

15

40

Male

–

Not stated

BBIBP–CorV

10 days after the both

[25]

16

45

Male

–

Not stated

BBIBP–CorV

7 days after the both

[25]

17

45

Male

–

Not stated

ChAdOx1-S

7 days after the 1st dose

[25]

18

49

Female

–

Not stated

BBIBP–CorV

10 days after the 1st dose

[25]

19

Psoriasis exacerbation

50

Male

Arthritis

Not stated

BBIBP–CorV

4 days after the first dose, 6 days after the 2nd dose

[25]

20

Bullous pemphigoid

85

Female

–

Not stated

BBIBP–CorV

20 days after the 1st dose

[25]

21

91

Male

–

Not stated

BBIBP–CorV

19 days after the 1st dose

[25]

22

Cutaneous vasculitis

45

Male

–

Not stated

BBIBP–CorV

2 days after the 1st dose

[25]

23

Pityriasis rosea

26

Male

Hypertension, diabetes mellitus

Not stated

BBIBP–CorV

14 days after the booster

[25]

24

Herpes zoster

60

Female

–

Not stated

BBIBP–CorV

6 days after the 1st dose

[25]

25

Urticaria and erythema multiform

31

Male

–

Not stated

BBIBP–CorV

11 days after the 2nd dose

[25]

26

32

Female

–

Not stated

ChAdOx1-S

20 days after the 1st

[25]

27

Morphea

35

Female

Hyperlipidemia, diabetes

Not stated

ChAdOx1-S

10 days after the 1st

[25]

28

Steven–Johnson syndrome

63

Female

Mild plaque-type psoriasis

type II diabetes mellitus

Not stated

BBIBP–CorV

24h after vaccination

[30]